ArticleJournal of biomedical physics & engineering2024
A Critical Look at Heavy Ion Beam Irradiation for Vaccine Development.
Article in Journal of biomedical physics & engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies offer valuable insights into viral inactivation for vaccine development. Schulze et al. have demonstrated the potential of heavy ion beam irradiation to create effective vaccines, which is particularly relevant in the context of airborne pandemics. Notably, the success in immunizing mice via intranasal administration with the inactivated influenza virus is encouraging, especially given the genetic similarities between influenza and SARS-CoV-2. However, the study raises important considerations. While heavy ion treatment shows advantages, there are concerns about viral inactivation completeness and the potential for surviving viruses, albeit at extremely low levels. Prolonged irradiation times and the risk of selective pressure leading to the evolution of resistant variants are highlighted. Biosafety concerns regarding accidental lab escape of resistant strains are crucial, emphasizing the need for caution during experiments. Moreover, limitations in Monte Carlo simulations of virus irradiation are discussed, pointing out the need for more comprehensive studies to assess the impact of secondary particles on virus inactivation under realistic irradiation conditions. Given these considerations, while the study presents a promising approach for vaccine development, further research is essential to address potential drawbacks and optimize the method for safe and effective application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.